Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.62−0.37 (-2.18%)
Close on Nov 19, 2026Market cap $3.03BP/E –Yield –
Xeris Biopharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Xeris Biopharma's revenue for the twelve months ending Jun 30, 2026 was $335.41M, up 36.3% year over year. For fiscal 2025 it was $291.85M, up 43.7% from the year before. The highest annual figure on record is $291.85M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $291.85M | +43.7% |
| FY2024 | Dec 31, 2024 | $203.07M | +23.9% |
| FY2023 | Dec 31, 2023 | $163.91M | +48.7% |
| FY2022 | Dec 31, 2022 | $110.25M | +122.3% |
| FY2021 | Dec 31, 2021 | $49.59M | +142.7% |
| FY2020 | Dec 31, 2020 | $20.44M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $92.10M | +28.7% |
| Q1 FY2026 | Mar 31, 2026 | $83.13M | +38.3% |
| Q4 FY2025 | Dec 31, 2025 | $85.81M | +42.8% |
| Q3 FY2025 | Sep 30, 2025 | $74.38M | +37.1% |
| Q2 FY2025 | Jun 30, 2025 | $71.54M | +48.8% |
| Q1 FY2025 | Mar 31, 2025 | $60.12M | +47.9% |
| Q4 FY2024 | Dec 31, 2024 | $60.10M | +35.4% |
| Q3 FY2024 | Sep 30, 2024 | $54.27M | +12.3% |
| Q2 FY2024 | Jun 30, 2024 | $48.07M | +26.5% |
| Q1 FY2024 | Mar 31, 2024 | $40.64M | +22.4% |
| Q4 FY2023 | Dec 31, 2023 | $44.39M | +33.9% |
| Q3 FY2023 | Sep 30, 2023 | $48.32M | +62.6% |
| Q2 FY2023 | Jun 30, 2023 | $38.01M | +50.2% |
| Q1 FY2023 | Mar 31, 2023 | $33.20M | +50.4% |
| Q4 FY2022 | Dec 31, 2022 | $33.14M | +54.7% |
| Q3 FY2022 | Sep 30, 2022 | $29.73M | +168.8% |
| Q2 FY2022 | Jun 30, 2022 | $25.31M | +184.1% |
| Q1 FY2022 | Mar 31, 2022 | $22.07M | +169.3% |
| Q4 FY2021 | Dec 31, 2021 | $21.43M | +190.8% |
| Q3 FY2021 | Sep 30, 2021 | $11.06M | +17.6% |
| Q2 FY2021 | Jun 30, 2021 | $8.91M | – |
| Q1 FY2021 | Mar 31, 2021 | $8.20M | – |
| Q4 FY2020 | Dec 31, 2020 | $7.37M | – |
| Q3 FY2020 | Sep 30, 2020 | $9.40M | – |
See a number that looks wrong?